Integrating New and Emerging Therapies into the Treatment Paradigm in Hepatocellular Carcinoma (HCC): Expert Strategies for Improved Patient Outcomes

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2018 Fall Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from February 1, 2019 to February 1, 2020

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by an educational grant from
Exelixis, Inc.

Hepatocellular carcinoma (HCC) is the most common type of liver cancer, accounting for about 90% of cases of primary liver cancer in the United States. In 2017, it was expected that liver cancer accounted for approximately 788,000 deaths globally, making it the second leading cause of cancer-related deaths worldwide. The prevalence and mortality rate of liver cancer has been rising steadily over the past decade. Prognosis is especially poor for those with unresectable HCC. For the treatment of HCC, transplantation is an option for patients, however, there is a limited supply of good-quality deceased donor organs. Thus, other treatments, including systemic therapy, should be used to bridge patients to transplant or to delay recurrence if possible in unresectable HCC.

Fortunately, clinicians have been equipped with new individualized options in the past year, including targeted therapies, which provide options for the unmet need of treatment in HCC, especially beyond first-line therapy. Tyrosine kinase inhibitors (TKIs) options have shown improved efficacy and safety in HCC, and healthcare professionals must be educated on these options, how they should be integrated into the treatment paradigm, and the potential risks that come along with any treatment option.

Upon completion of this activity, participants will be able to:

  • Examine the mechanisms of action, safety and efficacy of new and emerging targeted agents in the treatment of advanced hepatocellular carcinoma (HCC)

  • Analyze the role of emerging targeted options for advanced HCC beyond first-line therapy

  • Integrate recent clinical data and guideline recommendations into personalized decisions about the optimal use of targeted therapy in treatment protocols for patients with advanced HCC

  • Identify patients with advanced HCC for whom a targeted agent is an appropriate choice for the next step in the management of their cancer

  • Evaluate strategies to mitigate adverse events related to treatment with emerging targeted agents in patients with advanced HCC

Faculty: Ahmed Omar Kaseb, MD, CMQ
Associate Professor and Director
Hepatocellular Carcinoma Program
Editor-in-Chief, Journal of Hepatocellular Carcinoma
The University of Texas MD Anderson Cancer Center


Dr. Kaseb serves on an advisory board for Bayer/Onyx, Bristol-Myers Squibb, Eisai, Exelixis, and Merck. He serves as a consultant for Bayer/Onyx, Bristol-Myers Squibb, Eisai, Exelixis, and Merck. He has received grant/research support from Bayer/Onyx, Bristol-Myers Squibb, Eisai, and Merck. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses (AAMCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hour toward CMCN recertification requirements.

This presentation is supported by an educational grant from
Exelixis, Inc.

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue